Search Tag: Janssen COVID-19 vaccine

Executive Health Management

Ema-developments-for-sputnik-v-and-janssen-covid-19-vaccines

2021 05 Mar

The European Medicines Agency (EMA) has launched a rolling review of the Russian Sputnik V vaccine and is convening to potentially finalise the COVID-19 Vaccine Janssen’s marketing authorisation.   You might also like: The European Ombudsman is investigating the European Commission’s refusal to give public access to...Read more

Executive Health Management

Emas-conclusion-on-janssen-vaccine-and-blood-clots

2021 21 Apr

The European Medicines Agency has completed its safety review for Johnson & Johnson’s COVID-19 Vaccine Janssen giving conclusions similar to those on AstraZeneca’s Vaxzevria.   You might also like: EMA announced that the single dose Covid-19 vaccine has been approved for use in individuals 18 years of age and older in the European...Read more

Executive Health Management

Two-doses-make-johnson-johnson-covid-19-vaccine-94-effective

2021 22 Sep

In July, New York University researchers published results (Tada et. al, 2021) indicating the one-shot Johnson & Johnson (J&J) vaccine was less effective at preventing Delta variant infections. Although the study is not yet peer-reviewed, this finding is troubling given that the Delta variant now accounts for most US COVID-19 cases. Booster doses were...Read more

Executive Health Management

U-s-fda-backs-j-j-covid-19-vaccine-boosters

2021 19 Oct

On Friday, 15 October, a U.S. FDA advisory committee unanimously recommended that all adults that received the Johnson & Johnson (J&J) COVID-19 vaccine get a booster shot at least two months after their first shot. J&J now joins Pfizer and Moderna in gaining an FDA recommendation for a booster.   Unlike the Pfizer and Moderna recommendations which...Read more